## **Core Concept**
Aztreonam is a **monobactam antibiotic**, specifically designed to target **Gram-negative bacteria**. It works by inhibiting cell wall synthesis, similar to other beta-lactam antibiotics but with a unique structure that provides resistance to beta-lactamase enzymes.

## **Why the Correct Answer is Right**
Aztreonam's mechanism involves binding to **penicillin-binding proteins (PBPs)**, which are essential for bacterial cell wall synthesis. This binding inhibits the cross-linking of peptidoglycan layers, ultimately leading to cell lysis and death. Its effectiveness against Gram-negative bacteria, including many strains resistant to other antibiotics, makes it a valuable therapeutic option.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Not specified, as the actual options are missing. Generally, incorrect options regarding aztreonam might include statements about its spectrum, mechanism, or side effects that do not align with known properties.
- **Option B:** Similarly, without specifics, one might expect incorrect statements to contradict aztreonam's pharmacological profile, such as incorrect classifications as a **carbapenem** or claims of efficacy against **Gram-positive bacteria** or **anaerobic bacteria**.
- **Option C:**
- **Option D:**

## **Clinical Pearl / High-Yield Fact**
A key point to remember about aztreonam is its **low toxicity profile** and lack of cross-reactivity with other beta-lactam antibiotics in patients with severe allergies, making it a safe option for patients with significant allergy histories. Additionally, aztreonam is **not effective against Gram-positive bacteria** or **anaerobic bacteria**, which limits its use to specific infections.

## **Correct Answer:** D. Effective against anaerobic bacteria.
Aztreonam is not effective against anaerobic bacteria, making option D the statement that is not true about aztreonam.